Alternativas tecnológicas para aumentar a biodisponibilidade de anti-inflamatórios: gel mucoadesivo termorreversível e aplicação de sílica mesoporosa para amorfização

• Autor(a) principal: Antonino, Rayane Santa Cruz Martins de Queiroz
• Data de Publicação: 2020
• Tipo de documento: Tese
• Idioma: por
• Título da fonte: Repositório Institucional da UFG
• Texto Completo: http://repositorio.bc.ufg.br/tede/handle/tede/10559
• topic: Mucoadesão; Gel termorreversível; Biodisponibilidade; Anti-inflamatórios; Sílica mesoporosa; Thermoreversible gel; Bioavailability; Anti-inflammatories; Mesoporous silica; Mucoadhesion; CIENCIAS DA SAUDE::FARMACIA

Improving the therapeutic response of drugs is one of the major goals of pharmaceutical technology. This large area of research and development uses multidisciplinary technologies and knowledge aimed at optimizing drug delivery systems. It seeks, for example, to reduce side effects with the application of nanoparticulate systems (Chung et al., 2019), to improve the reach of drugs in the central nervous system (CNS) through new delivery and administration systems (Qureshi et al., 2019), increase the delivery and therapeutic action of drugs by promoting longer drug contact time at the site of action, such as the development of mucoadhesive formulations for the treatment of inflamed mucous membranes (Léber et al., 2019). It also seeks to increase the bioavailability of drugs with low aqueous solubility by obtaining the amorphous form of the drug either through porous adsorbent systems, such as mesoporous silicas, but also to increase the stability of the amorphous form in relation to the storage time (Zůza et al., 2019). The search for better therapeutic efficacy of drugs was the main motivation for this research, using different technologies for the development of formulations with different therapeutic objectives and targets. The first part of this research aimed to develop a mucoadhesive in situ thermoreversible gel, capturing a corticosteroid for the treatment of mucous regions with inflammation. This first part produced three scientific publications that are organized as the first two chapters of this document and an annex. The second part of the research aimed to investigate the adsorbent role of mesoporous silica in two different drugs in terms of the tendency to crystallization, aiming beyond bioavailability to increase the physical stability of the systems and the impact of the drugs on the storage of the systems. Through the development of this study, a scientific article was produced presented in the third and last chapter of this document. In summary, the research developed during the PhD period is organized in two parts, in which: Chapter 01 - This chapter has mucoadhesion as its central theme, and constitutes a review of the literature published as a chapter in the book “Sciences applied to health products”, by the publisher of the State University of Goiás in 2019, ISBN 978-85-5582- 060-1 (annex 3). Strategies for the development of new mucoadhesive pharmaceutical forms, mucus and its function in the human body, the theories that analyze mucoadhesion, the mucoadhesive formulations already available and the techniques and assays used to quantify mucoadhesion were covered in this chapter. Chapter 02 - In this chapter we describe the development and characterization in vitro / in vivo of a mucoadhesive in situ gelling formulation using poloxamer 407 (Pluronic® F 127), a thermoreversible polymer, capturing budesonide (BUD), a potent corticosteroid used for treatment of a wide range of inflammatory diseases, including those that affect mucous membranes, such as in the gastrointestinal tract. This chapter was published in 2019 as an original article in the Journal of Controlled Release, entitled Thermoreversible mucoadhesive polymer-drug dispersion for sustained local delivery of budesonide to treat inflammatory disorders of the GI tract (appendix 4). The term with the approval by the ethics committee for the use of animals is attached (annex 1). Another publication, referring to oral pharmaceutical compositions of corticosteroids that gel in situ, was the production of a patent (annex 2). Patent filed and published at the United States Patent and Trademark Office, with international application under Patent Cooperation Treaty (PCT), WO 2018/193423 A1, 2018. This patent is the result of a partnership between the University and a pharmaceutical industry, Ferring Pharmaceuticals, established for the development of mucoadhesive pharmaceutical formulations. In turn, depending on the second part, which deals with technologies aimed at optimizing bioavailability and promoting greater stability using porous adsorbent systems, we have chapter 3. Chapter 03 - In this chapter, a method has been described to determine the monolayer loading capacity (MLC) of naproxen, a weak drug to amorphize, in mesoporous silica (MS). MS can be used as a carrier to stabilize the amorphous form of a drug. In addition, the impact of monolayer, pore filling and excess, on the physical stability of this system was studied and compared to ibuprofen, a strong drug to amorphize. Finally, we investigated the impact of drug loading on storage below and above the glass transition temperature (Tg), in particular with a focus on the amorphous (in) stability of the confined drug, for both drugs. Using Theoretical Functional Density Theory (DFT) and Molecular Dynamics ab initio (AIMD), the binding energies for the monolayer suggest that the monolayer is thermodynamically more favorable than the crystalline form, while the confined amorphous form is thermodynamically less favorable. This chapter was published as an original article in the International Journal of Pharmaceutics: X, in 2019 (Annex 5).